Key Changes Under the Inflation Reduction Act

The Centers for Medicare & Medicaid Services (CMS) has released the final guidance for the 2027 Medicare Part D benefit year, implementing several provisions of the Inflation Reduction Act. These changes aim to reduce prescription drug costs for millions of Medicare beneficiaries.

Major Policy Updates

• $2,000 Annual Out-of-Pocket Cap: Beginning January 1, 2027, Medicare Part D enrollees will have their annual out-of-pocket spending on covered prescription drugs capped at $2,000. Once the cap is reached, the plan pays 100% of covered drug costs for the remainder of the year.
• Expanded Drug Coverage: Part D plans must now cover a broader range of medications in six protected classes, including immunosuppressants, antidepressants, and antiretroviral drugs, with limited use of prior authorization and step therapy.
• Monthly Payment Option: Beneficiaries can opt to pay their out-of-pocket costs in monthly installments rather than all at once at the pharmacy counter.
• Insulin Price Cap: The $35 monthly cap on insulin costs, which took effect in 2024, will continue through 2027 and beyond.

Impact on Community Pharmacies

Pharmacies will need to update their point-of-sale systems to accommodate the new cap calculation and installment payment options. We also anticipate increased patient inquiries about plan coverage and formulary changes. Our staff is preparing to assist patients in understanding their benefits and accessing affordable medications.

Free Medicare Part D Review

If you are a Medicare beneficiary, we invite you to schedule a complimentary medication review with our pharmacist. We can help you understand how these changes affect your coverage and explore cost-saving options, including generic alternatives and manufacturer assistance programs.

This summary is for informational purposes only. For personalized advice, please contact our pharmacy or your Medicare plan provider.